{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["53(3)"],"submitter":["Nakamura S"],"funding":["Shire Human Genetic Therapies, Inc., a Takeda company, Cambridge, MA, USA"],"pubmed_abstract":["<h4>Purpose</h4>The short- and long-term efficacy, safety, and pharmacokinetics of teduglutide were analyzed in adult Japanese patients with short bowel syndrome and intestinal failure (SBS-IF).<h4>Methods</h4>Patients received teduglutide 0.05 mg/kg/day in clinical trials (TED-C14-004, SHP633-306, and extension SHP633-307). Data were analyzed at 24 weeks and an interim data cut-off of 4.5 years.<h4>Results</h4>The parenteral support (PS) volume decreased by ≥ 20% for 9/18 patients at 24 weeks and in all 11 patients by data cut-off in SHP633-307. The mean (standard deviation) PS volume decreased from baseline at 24 weeks in TED-C14-004 (-30.1 ± 25.9%) and SHP633-306 (-25.6 ± 25.5%), and at data cut-off in SHP633-307 (-57.08 ± 28.49%). Teduglutide was absorbed quickly. The adverse events we"],"journal":["Surgery today"],"pagination":["347-359"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9950205"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension."],"pmcid":["PMC9950205"],"pubmed_authors":["Suzuki RK","Grimm A","Ohge H","Udagawa E","Chen ST","Sugita A","Tazuke Y","Mizushima T","Ikeuchi H","Nakamura S","Yoon M","Wada M"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension.","description":"<h4>Purpose</h4>The short- and long-term efficacy, safety, and pharmacokinetics of teduglutide were analyzed in adult Japanese patients with short bowel syndrome and intestinal failure (SBS-IF).<h4>Methods</h4>Patients received teduglutide 0.05 mg/kg/day in clinical trials (TED-C14-004, SHP633-306, and extension SHP633-307). Data were analyzed at 24 weeks and an interim data cut-off of 4.5 years.<h4>Results</h4>The parenteral support (PS) volume decreased by ≥ 20% for 9/18 patients at 24 weeks and in all 11 patients by data cut-off in SHP633-307. The mean (standard deviation) PS volume decreased from baseline at 24 weeks in TED-C14-004 (-30.1 ± 25.9%) and SHP633-306 (-25.6 ± 25.5%), and at data cut-off in SHP633-307 (-57.08 ± 28.49%). Teduglutide was absorbed quickly. The adverse events we","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-05-29T05:29:50.465Z","creation":"2025-02-18T23:44:41.129Z"},"accession":"S-EPMC9950205","cross_references":{"pubmed":["36201060"],"doi":["10.1007/s00595-022-02587-4"]}}